<DOC>
	<DOCNO>NCT00036972</DOCNO>
	<brief_summary>RATIONALE : Immunotoxins locate tumor cell kill without harm normal cell . Immunotoxin therapy may effective treat malignant glioma . PURPOSE : Phase I trial study effectiveness immunotoxin therapy surgery treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Immunotoxin Therapy Before After Surgery Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine concentration interleukin-13 PE38QQR immunotoxin produce histologic evidence toxicity tumor correspond toxic effect drug administer via continuous intratumoral infusion prior second resection patient recurrent resectable supratentorial malignant glioma . - Determine toxic effect drug administer via continuous peritumoral infusion , concentration determine objective I , second resection patient . - Determine toxic effect increase duration continuous peritumoral infusion drug , concentration determine objective II , second resection patient . - Determine time progression survival patient treat regimen . OUTLINE : This dose-escalation , multicenter study . - Pre-resection therapy ( initial cohort patient ) : Patients undergo stereotactic biopsy brain tumor follow stereotactic placement 1 intratumoral catheter day 1 . Patients histologically confirm malignant glioma receive interleukin-13 PE38QQR immunotoxin via continuous intratumoral infusion 48 hour day 2 3 . Cohorts 3-6 patient receive escalate dos pre-resection interleukin-13 PE38QQR immunotoxin histologically effective concentration ( HEC ) reach maximum tolerated dose ( MTD ) determine . The HEC define pathologic observation . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . After HEC reach MTD determine , 6 additional patient enrol select dose level study safety tolerability . Subsequent cohort patient treat pre-resection infusion . - Resection ( patient ) : Patients undergo maximal resection ( en bloc , feasible ) follow placement 2-3 peritumoral catheter ( 4 day completion pre-resection infusion initial cohort patient study entry subsequent cohort patient ) . - Post-resection therapy ( patient ) : Beginning second day resection , patient receive interleukin-13 PE38QQR immunotoxin via continuous peritumoral infusion 96 hour . Cohorts 3-6 patient receive escalate dos interleukin-13 PE38QQR immunotoxin previously-defined HEC reach MTD determine , whichever occur first . If dose-escalation stop HEC reach , three additional cohort patient receive escalate duration ( 5 , 6 , 7 day ) post-resection infusion . If dose escalation stop MTD determine , duration post-resection infusion escalate . Patients follow every 8 week . PROJECTED ACCRUAL : A total 25-50 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial malignant glioma ( grade 3 4 ) Anaplastic astrocytoma Glioblastoma multiforme Mixed oligoastrocytoma Malignant astrocytoma , otherwise specify Prior first resection brain tumor Prior cranial radiotherapy tumor dose least 48 Gy Radiographic evidence recurrent progressive supratentorial tumor In patient receive external beam radiotherapy localize radiotherapy ( e.g. , gammaknife brachytherapy ) within past 12 week , progression must confirm metabolic imaging ( magnetic resonance spectroscopy positronemission tomography ) Must candidate second resection No sign impend herniation No midline shift great 1 cm No multifocal disease subependymal tumor spread PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : PT PTT great upper limit normal Renal : Not specify Other : No uncontrolled seizures No neurologic condition would interfere study evaluation Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 60 day study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior cytotoxic therapy ( 2 week vincristine 6 week nitrosoureas ) Endocrine therapy : Concurrent steroid allow No taper steroid immediately study infusion Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : Recovered prior therapy At least 4 week since prior investigational agent At least 2 week since prior noncytotoxic agent No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>